Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 24, 2015, Pages 4827-4834

  Yan, H ^a   Zhao, R M ^b   Wang, Z J ^c   Zhao, F R ^d   Wang, S L ^b  

^a PEOPLE S HOSPITAL OF RIZHAO   (China)

^b Departmet of General Surgery   (China)

^c WEIFANG PEOPLE'S HOSPITAL   (China)

^d People s Hospital of Zhangqiu   (China)

Author keywords

Chemotherapy; Chronic myeloid leukemia; PRAME

Indexed keywords

DOXORUBICIN; MELANOMA ANTIGEN; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PRAME PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; K562 CELL LINE; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR REGRESSION; WEIGHT REDUCTION; DRUG EFFECTS; GENETICS; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOXORUBICIN; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

EID: 84966290835     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. BONNET D, DICK J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
2. HAMILTON A, HELGASON GV, SCHEMIONEK M. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501-1510
3. ESTEY EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013; 88: 318-327.
4. STEFANACHI A, LEONETTI F, NICOLOTTI O, CATTO M, PISANI L, CELLAMARE S. New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia. Curr Cancer Drug Targets 2014; 12: 571-596.
5. FERRARA F. New agents for acute myeloid leukemia: is it time for targeted therapies? Expert Opin Investig Drugs 2015; 21:179-189.
6. HOLYOAKE TL, HELGASON GV. Do we need more drugs for chronic myeloid leukemia? Immunol Rev 2015; 263: 106-123.
7. KESSLER JH, BEEKMAN NJ, BRES-VLOEMANS SA, VERDIJK P, VAN VEELEN PA, KLOOSTERMAN-JOOSTEN AM. Efficient identificat ion of novel HLAA(∗) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193: 73-88.
8. LUETKENS T, SCHAFHAUSEN P, UHLICH F, STASCHE T, AKBULAK R, BARTELS BM, HILDEBRANDT Y, GONTAREWICZ A, KOBOLD S, MEYER S, GORDIC M, BARTELS K, LAJMI N, CAO Y, KRÖGER N, BOKEMEYER C, BRÜMMENDORF TH, ATANACKOVIC D. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 2010; 34: 1647-1655.
9. DING K, WANG XM, FU R, RUAN EB, LIU H, SHAO ZH. PRAME gene expression in acute leukemia and its clinical significance. Cancer Biol Med 2012; 9: 73-76.
10. TANAKA N, WANG YH, SHISEKI M, TAKANASHI M, MOTOJI T. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res 2011; 35: 1219-1225.
11. BULLINGER L, SCHLENK RF, GÖTZ M, BOTZENHARDT U, HOFMANN S, RUSS AC, BABIAK A, ZHANG L, SCHNEIDER V, DÖHNER K, SCHMITT M, DÖHNER H, GREINER J. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation-a possible target for ATRA response in AML without t(15;17). Clin Cancer Res 2013; 19: 2562-2571.
12. REDNER RL. PRAMEing a picture of differentiation therapy for AML? Clin Cancer Res 2013; 19: 2277-2279.
13. DEVI RS. siRNA-based approaches in cancer therapy. Cancer Gene Ther 2006; 13: 819-829.
14. ODATE S, NAKAMURA K, ONISHI H, KOJIMA M, UCHIYAMA A, NAKANO K, KATO M, TANAKA M, KATANO M. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer 2013; 79: 205-214.
15. WANG Z, ZHOU J, FAN J, QIU SJ, YU Y, HUANG XW, TANG ZY. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 5124-5130.
16. KEWITZ S, STAEGE MS. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS One 2013; 8: e55897.
17. GOELLNER S, STEINBACH D, SCHENK T, GRUHN B, ZINTL F, RAMSAY E, SALUZ HP. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis-and MDR-related gene expression. Eur J Cancer 2006; 42: 2807-2814.